BeOne Medicines (ONC) Form 144 Discloses 9,010 ADS Sale via Morgan Stanley

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) Form 144 notice reports a proposed sale of 9,010 ADS (American Depositary Shares) through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $3,163,681.30 and approximately 54,564,278 ADS outstanding. The filing shows the securities were mainly acquired via an exercise of stock options on 09/10/2025 (8,894 ADS, paid in cash) and restricted stock units on 06/15/2025 (116 ADS). The filer disclosed prior sales in the past three months: 9,342 ADS (10b5-1 sale) on 08/13/2025 for $2,805,905.17, 920 ADS on 07/30/2025 for $280,232.74, and 422 ADS on 06/16/2025 for $112,463.00. The notice includes the usual representation about absence of undisclosed material adverse information and reference to Rule 10b5-1 trading plans where applicable.

Positive

• Transparent disclosure of proposed sale details including broker, number of ADS, aggregate value, and exchange
• Source of shares documented (exercise of stock options and restricted stock units) with acquisition and payment dates
• Prior three-month sales reported, including a 10b5-1 sale, showing consistency with disclosure obligations

Negative

• Insider selling activity of 9,010 ADS valued at $3,163,681.30 could represent notable insider liquidity
• Concentration of recent sales (10,684 ADS sold in past three months) may warrant investor attention regarding insider disposition

Insights

Securities Analyst

TL;DR: Insider plans to sell 9,010 ADS valued at $3.16M; recent 10b5-1 sales totaling 10,684 ADS were also disclosed.

The filing documents a proposed sale executed through Morgan Stanley Smith Barney LLC of 9,010 ADS valued at $3,163,681.30, with most of the shares acquired by option exercise on the same date. The schedule of prior sales shows systematic disposals over the last three months, including a 10b5-1 sale of 9,342 ADS on 08/13/2025. From a trading-impact perspective, the disclosure is clear and follows Rule 144 reporting requirements; it allows investors to see insider liquidity events and the mechanical origin of the shares (options and RSUs).

Corporate Governance Expert

TL;DR: Filing is a routine insider disclosure showing option exercise and subsequent planned sales; governance disclosure appears compliant.

The document identifies the nature of acquisition (exercise of stock options and RSUs) and provides dates and payment method (cash for the option exercise). It includes prior sales over the past three months and references Rule 10b5-1 where applicable, along with the required signer representation about undisclosed material information. Based solely on the filing text, the disclosure meets standard Form 144 content requirements without additional governance issues noted in the filing itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9010	3163681.30	54564278	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	09/10/2025	Exercise of Stock Options	Issuer			8894	09/10/2025	Cash
ADS	06/15/2025	Restricted Stock Units	Issuer			116	06/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	08/13/2025	9342	2805905.17
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/30/2025	920	280232.74
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	06/16/2025	422	112463.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the Form 144 for ONC report for proposed sale?

The filing reports a proposed sale of 9,010 ADS (American Depositary Shares) on NASDAQ through Morgan Stanley Smith Barney LLC.

What is the aggregate market value of the ADS proposed for sale?

The aggregate market value reported for the 9,010 ADS is $3,163,681.30.

How were the ADS being sold acquired according to the filing?

Most shares were acquired via an exercise of stock options on 09/10/2025 (8,894 ADS, paid in cash) and 116 ADS were acquired as restricted stock units on 06/15/2025.

Does the filing report recent past sales by the same person?

Yes. The filing lists sales in the past three months: 9,342 ADS on 08/13/2025 for $2,805,905.17 (10b5-1 sale), 920 ADS on 07/30/2025 for $280,232.74, and 422 ADS on 06/16/2025 for $112,463.00.

Did the filer indicate reliance on a Rule 10b5-1 trading plan?

The filing references a 10b5-1 sale in the prior sales table and includes the standard representation regarding adoption of a written trading plan where applicable.